logowsbdaily | Wed, 10 Aug 2022 07:32:31 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Aldeyra Therapeutics, Inc.
(ALDX)

Aldeyra Therapeutics, Inc.
131 Hartwell Avenue
Suite 320
Lexington, MA 02421
United States
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-219... Read More

Summary & Charts

Price$ 5.22+0.14 (+2.75%)
Day's Range$ 4.80 - 5.24 
Previous Close$ 5.08
Market Cap$ 304.33M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqCM
IndustryBiotechnology
SectorHealthcare
Volume840.29K
Avg. Volume (20 day)1.32M
Rel. Volume (20 day)0.64
Rel. Volume (3 month)0.80
RatingB+Buy
DCFN/AStrong Buy
Debt/Equity16.78 %Neutral
ROE-27198.65 %Neutral
ROA-25946.83 %Neutral
P/E-0.01 %Strong Sell
P/B1.60 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Jul 22, 2022$ 5.09$ 5.24$ 4.80$ 5.22+0.14840,2940.640.80
Jul 21, 2022$ 5.14$ 5.14$ 5.00$ 5.08-0.05402,4730.300.39
Jul 20, 2022$ 5.10$ 5.39$ 5.00$ 5.13+0.101,293,0060.941.25
Jul 19, 2022$ 4.79$ 5.14$ 4.79$ 5.03+0.25768,5360.550.76
Jul 18, 2022$ 4.80$ 4.95$ 4.71$ 4.78+0.061,052,9340.751.05
Jul 15, 2022$ 5.39$ 5.41$ 4.67$ 4.72-0.591,468,9441.051.47
Jul 14, 2022$ 5.30$ 5.33$ 4.99$ 5.31+0.081,220,9810.901.26
Jul 13, 2022$ 4.95$ 5.56$ 4.89$ 5.23+0.092,301,8141.722.41
Jul 12, 2022$ 4.55$ 5.26$ 4.26$ 5.14+0.673,989,0253.114.32
Jul 11, 2022$ 4.50$ 4.59$ 4.45$ 4.47-0.02579,1690.510.65
Jul 08, 2022$ 4.24$ 4.51$ 4.23$ 4.49+0.15749,8510.600.84
Jul 07, 2022$ 4.21$ 4.42$ 4.20$ 4.34+0.19476,1820.330.53
Jul 06, 2022$ 4.03$ 4.29$ 4.02$ 4.15+0.12551,3690.370.61
Jul 05, 2022$ 3.73$ 4.05$ 3.72$ 4.03+0.23547,0420.370.60
Jul 01, 2022$ 3.97$ 4.07$ 3.76$ 3.80-0.19577,1330.390.63
Jun 30, 2022$ 3.81$ 4.04$ 3.81$ 3.99+0.06564,3650.390.61
Jun 29, 2022$ 3.96$ 4.01$ 3.81$ 3.93-0.06644,2460.440.70
Jun 28, 2022$ 3.95$ 4.04$ 3.87$ 3.99+0.12755,2920.520.81
Jun 27, 2022$ 3.78$ 3.93$ 3.58$ 3.87+0.191,046,8790.731.12
Jun 24, 2022$ 3.62$ 3.74$ 3.43$ 3.68+0.096,581,4764.727.06

News

The latest news about Aldeyra Therapeutics, Inc. (ALDX).

Zacks Investment Research | 2022-07-13 13:05:35
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Benzinga | 2022-07-12 09:03:04
Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate for dry eye disease.  Relative to the vehicle, a statistically significant reduction in ocular.
Business Wire | 2022-07-11 16:05:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report top-line results from the crossover clinical trial of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease. The dial-in numbers are (844) 200-6205 for domestic callers and (646) 904-5544 for international callers. The access code is 853619. A live audio webcast o
Benzinga | 2022-06-08 09:47:04
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test and ≥10 mm Schirmer.
Business Wire | 2022-06-07 16:05:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 879247. A live audio webcast of the conference call also will be accessible from th
Business Wire | 2022-05-23 16:05:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. Dr. Brady's conversation with Matthew Caufield, Vice President, Equity Research for H.C. Wainwright, will be available o

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-08-04BMO-0.32----------
2022-05-05BMO-0.31-0.296.46%------
2022-03-17BMO-0.28-0.273.58%------
2021-10-28BMO-0.26-0.273.84%------
2021-08-05BMO-0.27-0.283.7%------
2021-05-06BMO-0.27-0.257.41%------
2021-03-11BMO-0.28-0.307.14%------
2020-11-05BMO-0.27-0.2314.82%------

Top Discussions

These are the top discussions over the last 24-hours that mention the ALDX stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.